Centene Corporation — Healthcare Plans. Scored on the same transparent 7-signal model behind the daily rankings.
★
CNC
Centene Corporation · Healthcare Plans
FCF$7.1bB+
Rev+19.4%B+
D/E0.76C+
P/S0.2xA
PEG1.27B
56.3Score
$67.60$33.4B
1Y Target$62.67Analyst consensus · 18 analysts
5Y Target$109.60Compound horizon
10Y Target$277.96Long-dated conviction
FCF$7.1bTTM · 03/26B+
FCF $7.1b — strong cash profile, above most peers · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+19.4%FY YoYB+
Revenue +19.4% — above sector median, healthy trajectory · Computed from last two annual revenue figures (FY YoY).
D/E0.76C+
D/E 0.76 — above the Healthcare debt median (≈75th pctile)
P/S0.2xA
P/S 0.2x — cheapest decile in Healthcare (≈10th pctile)
PEG1.27B
PEG 1.27 — acceptable premium for growth
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 56.3
Quality0.28
Growth0.92
Value0.69
Entry · Margin of safety
52-week rangeNear 52-week high
2% off the 12-month high
vs DCF fair value79% belowest. fair value ~$318
Why now
Healthcare Plans · market cap $33.4b. Trading near 52-week high of $69.29 — momentum setup, limited technical margin of safety. Revenue growing +19%, comfortably above the S&P median. 18 sell-side analysts rate this a Buy with a mean 1-yr target of $62.67 (implying -7% upside).
Moat
Turnaround / out-of-favor name — GAAP-unprofitable for now, so the durability case is forward-looking: it rests on a recovery (margin normalization, a cyclical upturn or restructuring) or an un-monetized asset (IP / network effects / first-mover position) rather than on current reported results.
Risk
Currently unprofitable (margin -3.6%) — path to GAAP profitability is the core thesis risk. Trading within 2% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. ROE -26% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Horizon
1-3 yr $62.67 (18-analyst consensus) — catalyst-driven; binary events dominate. 5 yr $109.60 — requires the platform / technology to reach commercial scale. 10 yr $277.96 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · CNC
$
%
%
Shares to buy
29
Position size
$1,960
3.9% of portfolio
Stop price
$50.70
25% below $67.60
$ at risk if stopped
$490.10
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Centene Corporation (CNC): score, valuation & FAQ
Centene Corporation (CNC) is a Healthcare Plans company that scores 56.3 out of 100 on the Bull Rankings quality-growth model — a middling reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are P/S (A), FCF (B+) and Rev (B+). On valuation, CNC sits about 79% below our discounted-cash-flow fair value (a margin of safety).
Is CNC a good stock to buy?
Bull Rankings scores CNC 56.3 out of 100 on its quality-growth model, which is a middling reading. That is driven by P/S (A), FCF (B+) and Rev (B+). A score is a quantitative screen of Centene Corporation's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does CNC score 56.3 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). CNC earns its highest marks on P/S (A), FCF (B+) and Rev (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is CNC overvalued or undervalued?
Based on $67.60, CNC sits about 79% below our discounted-cash-flow fair value (a margin of safety). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in CNC?
Currently unprofitable (margin -3.6%) — path to GAAP profitability is the core thesis risk. Trading within 2% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. ROE -26% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.